Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Advanced Genetic Technologies

2006 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of technologies for immune therapy to address the problem of multidrug resistant strains of HIV. The company holds the exclusive licenses for monoclonal antibodies TS1-18 and TS1-22 and non-exclusive rights to the bacterial plasmid 8630.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 2109 East Palm Avenue
  • Tampa, FL 33605
  • United States

Advanced Genetic Technologies Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Advanced Genetic Technologies‘s full profile, request access.

Request full access to PitchBook

Advanced Genetic Technologies Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Advanced Genetic Technologies‘s full profile, request access.

Request full access to PitchBook

Advanced Genetic Technologies Executive Team (2)

Name Title Board
Seat
Contact
Info
Timothy Springer Ph.D Founder

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »